Hepatotoxicity associated to synthetic cannabinoids use

被引：0

作者：

Solimini, R. ^{[1
]}

Busardo, F. P. ^{[2
]}

Rotolo, M. C. ^{[1
]}

Ricci, S. ^{[3
]}

Mastrobattista, L. ^{[1
]}

Mortali, C. ^{[1
]}

Graziano, S. ^{[1
]}

Pellegrini, M. ^{[1
]}

Di Luca, N. M. ^{[3
]}

Palmi, I. ^{[1
]}

机构：

[1] Ist Super Sanita, Drug Abuse & Doping Unit, Dept Therapeut Res & Med Evaluat, Rome, Italy

[2] Sapienza Univ Rome, Dept Anat Histol Forens & Orthoped Sci, Unit Forens Toxicol UoFT, Rome, Italy

[3] Sapienza Univ Rome, Dept Anat Histol Forens & Orthoped Sci, Sect Legal Med, Rome, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2017年 / 21卷

关键词：

Synthetic cannabinoids; Hepatotoxicity; Illicit use; CONSUMPTION; METABOLISM; JWH-018; DRUGS;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Synthetic cannabinoids (SCs) are psychotropic compounds, chemically created in laboratory to mimic cannabinergic brain activity of delta-9 tetrahydrocannabinol. The consumption of these compounds for recreational purposes can lead to a variety of adverse effects on health including overdose and deaths. Increasingly popular as substances of abuse since the 2000s, SCs were produced initially to bind and study cannabinoid receptors (they also can be called synthetic cannabimimetics) failing in eliminating the psychoactive effects. Currently, SCs are misused by students and young adults as "natural products" because of their herbal aspect. Actually, these apparently innocuous recreational substances hide toxic effects to health. Reported side effects are cardiovascular, gastrointestinal, neurological, renal, metabolic, ophthalmologic, pulmonary and psychoactive including dependence and withdrawal. A few cases of SCs ingestion have also been associated with liver failure. We herein review the recent literature on the SCs toxicity with particular attention to liver damage aspects.

引用

页码：1 / 6

页数：6

共 27 条

[1] Inhibitory effect of synthetic cannabinoids on CYPIA activity in mouse liver microsomes [J].

Ashino, Takashi ;

Hakukawa, Kanae ;

Itoh, Yuka ;

Numazawa, Satoshi .

JOURNAL OF TOXICOLOGICAL SCIENCES, 2014, 39 (06) :815-820

[2] Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22 [J].

Behonick, George ;

Shanks, Kevin G. ;

Firchau, Dennis J. ;

Mathur, Gagan ;

Lynch, Charles F. ;

Nashelsky, Marcus ;

Jaskierny, David J. ;

Meroueh, Chady .

JOURNAL OF ANALYTICAL TOXICOLOGY, 2014, 38 (08) :559-562

[3] Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications [J].

Castaneto, Marisol S. ;

Gorelick, David A. ;

Desrosiers, Nathalie A. ;

Hartman, Rebecca L. ;

Pirard, Sandrine ;

Huestis, Marilyn A. .

DRUG AND ALCOHOL DEPENDENCE, 2014, 144 :12-41

[4]

Castellanos Daniel, 2016, World J Clin Pediatr, V5, P16, DOI 10.5409/wjcp.v5.i1.16

[5]

Chimalakonda Krishna C, 2013, Drug Metab Lett, V7, P34

[6] Conjugation of Synthetic Cannabinoids JWH-018 and JWH-073, Metabolites by Human UDP-Glucuronosyltransferases [J].

Chimalakonda, Krishna C. ;

Bratton, Stacie M. ;

Le, Vi-Huyen ;

Yiew, Kan Hui ;

Dineva, Anna ;

Moran, Cindy L. ;

James, Laura P. ;

Moran, Jeffery H. ;

Radominska-Pandya, Anna .

DRUG METABOLISM AND DISPOSITION, 2011, 39 (10) :1967-1976

[7] Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis [J].

Deveaux, Vanessa ;

Cadoudal, Thomas ;

Ichigotani, Yasukatsu ;

Teixeira-Clerc, Fatima ;

Louvet, Alexandre ;

Manin, Sylvie ;

Tran-Van Nhieu, Jeanne ;

Belot, Marie Pierre ;

Zimmer, Andreas ;

Even, Patrick ;

Cani, Patrice D. ;

Knauf, Claude ;

Burcelin, Remy ;

Bertola, Adeline ;

Le Marchand-Brustel, Yannick ;

Gual, Philippe ;

Mallat, Ariane ;

Lotersztajn, Sophie .

PLOS ONE, 2009, 4 (06)

[8]

DRUG ENFORCEMENT ADMINISTRATION (DEA), 2015, FED REGISTER, V80, P55565

[9]

DRUG ENFORCEMENT ADMINISTRATION (DEA), 2015, DRUGS OF AB

[10]

EMCDDA, 2016, SYNTH CANN EUR

← 1 2 3 →